| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.072 | 0.1 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.046 | 0.1 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.2 |